JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, L.
Right arrow Articles by Thompson, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, L.
Right arrow Articles by Thompson, W. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 299, Issue 2, 583-592, November 2001

Cyclic GMP-Dependent Protein Kinase Activation and Induction by Exisulind and CP461 in Colon Tumor Cells

Li Liu, Han Li, Tashandra Underwood, Marti Lloyd, Mary David, Gerhard Sperl, Rifat Pamukcu and W. Joseph Thompson

Cell Pathways, Inc., Horsham, Pennsylvania (L.L., H.L., T.U., M.L., M.D., G.S., R.P., W.J.T.); and Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, Alabama (W.J.T.)

These studies report on the activation and induction of cGMP-dependent protein kinase (PKG) by exisulind and analogs and test the hypothesis that PKG is involved in the induction of apoptosis in colon tumor cells. Exisulind and analogs are proapoptotic drugs developed as inhibitors of cGMP phosphodiesterase gene families 5 and 2 that have been shown to sustain increased cGMP in SW480 and HT29 cells. At concentrations that induced apoptosis, both exisulind and CP461 increased PKG activity in SW480 cell supernatants. PKG activation was dose-dependent and sustained. Activation of PKG by exisulind and analogs was also seen in the colon tumor cell lines HT29, T84, and HCT116. The guanylyl cyclase activators YC-1 and guanylin increased PKG activity secondary to increased cellular cGMP and induced apoptosis in colon tumor cells. Exisulind and CP461 had no direct effect on purified PKG activity or on basal and stimulated PKG activity from cell supernatants. An additional effect of exisulind after 8 h of drug treatment was a dose-dependent increase of PKG Ibeta protein expression. beta -Catenin, a potential new substrate for PKG, whose regulation influences apoptosis, was phosphorylated by PKG in vitro. 32P-labeled cells treated with exisulind showed increased phosphorylation of beta -catenin. These data indicate that exisulind and analogs activate and induce PKG, resulting in increased phosphorylation of beta -catenin and enhanced apoptosis to promote colon tumor cell death.

0022-3565/01/2992-0583$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Exp. Med.Home page
P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
J. Exp. Med., November 27, 2006; 203(12): 2691 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. M. Pitari, T. Li, R. I. Baksh, and S. A. Waldman
Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1190 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Sindic and E. Schlatter
Cellular Effects of Guanylin and Uroguanylin
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 607 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Xiao, A. Deguchi, G. G. Gundersen, B. Oehlen, L. Arnold, and I. B. Weinstein
The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization
Mol. Cancer Ther., January 1, 2006; 5(1): 60 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Deguchi, W. J. Thompson, and I. B. Weinstein
Activation of Protein Kinase G Is Sufficient to Induce Apoptosis and Inhibit Cell Migration in Colon Cancer Cells
Cancer Res., June 1, 2004; 64(11): 3966 - 3973.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. L. Rice, J. Kelloff, H. Sullivan, L. J. Driggers, K. S. Beard, S. Kuwada, G. Piazza, and D. J. Ahnen
Sulindac metabolites induce caspase- and proteasome-dependent degradation of {beta}-catenin protein in human colon cancer cells
Mol. Cancer Ther., September 1, 2003; 2(9): 885 - 892.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. M. Whitehead, K. A. Earle, J. Fetter, S. Xu, T. Hartman, D. C. Chan, T. L. M. Zhao, G. Piazza, A. J.P. Klein-Szanto, R. Pamukcu, et al.
Exisulind-induced Apoptosis in a Non-Small Cell Lung Cancer Orthotopic Lung Tumor Model Augments Docetaxel Treatment and Contributes to Increased Survival
Mol. Cancer Ther., May 1, 2003; 2(5): 479 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. R. Kisley, B. S. Barrett, A. K. Bauer, L. D. Dwyer-Nield, B. Barthel, A. M. Meyer, D. C. Thompson, and A. M. Malkinson
Genetic Ablation of Inducible Nitric Oxide Synthase Decreases Mouse Lung Tumorigenesis
Cancer Res., December 1, 2002; 62(23): 6850 - 6856.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. A. Steinbrecher, S. A. Wowk, J. A. Rudolph, D. P. Witte, and M. B. Cohen
Targeted Inactivation of the Mouse Guanylin Gene Results in Altered Dynamics of Colonic Epithelial Proliferation
Am. J. Pathol., December 1, 2002; 161(6): 2169 - 2178.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Deguchi, J.-W. Soh, H. Li, R. Pamukcu, W. J. Thompson, and I. B. Weinstein
Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Provides a Biomarker for the Action of Exisulind and Related Agents That Activate Protein Kinase G
Mol. Cancer Ther., August 1, 2002; 1(10): 803 - 809.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.